Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

v3.24.2.u1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Revenues, net $ 2,474 $ 13,217 $ 6,108 $ 32,520
Cost of revenues 2,950 6,769 7,017 15,552
Gross (loss) profit (476) 6,448 (909) 16,968
Operating expenses:        
Diagnostic expenses 0 597 0 1,800
General and administration 7,212 9,937 14,805 18,235
Research and development 139 572 411 716
Total operating expenses 7,351 11,106 15,216 20,751
Loss from operations (7,827) (4,658) (16,125) (3,783)
Interest income, net 0 27 0 38
Interest expense (643) (291) (1,158) (506)
Other (expense) income 30 8 12 (99)
Loss from operations before income taxes (8,440) (4,914) (17,271) (4,350)
Income tax benefit 2,287 1,474 4,853 1,460
Loss from operations after income taxes (6,153) (3,440) (12,418) (2,890)
Net loss (6,153) (3,440) (12,418) (2,890)
Other comprehensive income (loss):        
Unrealized gain (loss) on marketable securities (58) 496 102 (169)
Total comprehensive loss $ (6,211) $ (2,944) $ (12,316) $ (3,059)
Loss per share:        
Basic (in dollars per share) $ (0.33) $ (0.20) $ (0.67) $ (0.17)
Diluted (in dollars per share) $ (0.33) $ (0.20) $ (0.67) $ (0.17)
Weighted average common shares outstanding:        
Weighted average common shares outstanding, basic (in shares) 18,888 16,845 18,466 16,797
Weighted average common shares outstanding, diluted (in shares) 18,888 16,845 18,466 16,797